Novo Nordisk A/S (CPH:NOVO.B)
Denmark · Delayed Price · Currency is DKK 248.75
-1.25 (-0.50%)
Oct 2, 2026, 4:59 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 78.49B DKK in the quarter ending June 30, 2026, with 2.12% growth. This brings the company's revenue in the last twelve months to 329.43B, up 5.61% year-over-year. In the year 2025, Novo Nordisk had annual revenue of 309.06B with 6.43% growth.
Revenue (ttm)
329.43B
Revenue Growth
+5.61%
P/S Ratio
3.34
Revenue / Employee
4.94M
Employees
66,700
Market Cap
1.10T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 28.44B |
| Genmab | 27.03B |
| H. Lundbeck | 25.96B |
| Demant | 24.63B |
| GN Store Nord | 16.46B |
| ALK-Abelló | 6.83B |
| Embla Medical | 6.44B |
| Bavarian Nordic | 6.34B |
Novo Nordisk News
- 1 day ago - Novo Nordisk Plans Denecimib U.S. Launch In H1 2027 Amid FDA Review Extension - Nasdaq
- 1 day ago - FDA Postpones Review of Novo Nordisk's Hemophilia A Drug, NVO Eyes 2027 U.S. Launch - GuruFocus
- 1 day ago - US FDA extends review of Novo Nordisk's hemophilia drug over facility issues - Reuters
- 1 day ago - Novo provides update on the denecimig Biologics License Application (BLA) in the US - GlobeNewsWire
- 1 day ago - Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors - The Motley Fool
- 1 day ago - Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
- 1 day ago - Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s - CNBC
- 2 days ago - Lightning Round: Sprouts is a winner, says Jim Cramer - CNBC